SRPTSarepta Therapeutics, Inc.
Pharmaceutical Preparations
- Revenue
- $1.9B
- 4.3% YoY
- Operating margin
- -37.5%
- 408% YoY
- EBITDA
- −$655M
- 356% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- —
- $276M net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear—Cash flow under 80% of net income
- Dilutive SBCClear7% of revenueOver 10% of revenue
- Payouts exceed cash flowClear-12% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $612M | $844M | $1.1B | $1.8B | $1.9B | 4.3% |
| Operating income | −$460M | −$536M | −$268M | $218M | −$700M | 421% |
| Net income | −$419M | −$703M | −$536M | $235M | −$713M | 403% |
| Operating cash flow | −$443M | −$325M | −$501M | −$206M | −$205M | 0.1% |
| Capex | $38M | $31M | $76M | $137M | $102M | 26% |
| Stock-based comp | $114M | $233M | $183M | $184M | $123M | 33% |
| Buybacks | — | — | $0 | $0 | $25M |
Deal filings
None.
13D filers
None on file.
Insider trading
No open-market trades in the last 12 months.
Pay vs performance
| Year | CEO total comp | Comp actually paid | TSR (indexed) | Peer TSR |
|---|---|---|---|---|
| FY2025 | $8M | −$17M | 13 | 125 |
| FY2024 | $2M | −$15M | 71 | 94 |
| FY2023 | $2M | −$35M | 57 | 94 |
| FY2022 | $125M | $163M | 76 | 90 |
| FY2021 | $2M | −$305M | 53 | 100 |